PMID- 19274364
OWN - NLM
STAT- MEDLINE
DCOM- 20090625
LR  - 20240323
IS  - 1564-0604 (Electronic)
IS  - 0042-9686 (Print)
IS  - 0042-9686 (Linking)
VI  - 87
IP  - 2
DP  - 2009 Feb
TI  - Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) 
      in Mozambique and the United Republic of Tanzania.
PG  - 123-9
LID - S0042-96862009000200014 [pii]
AB  - OBJECTIVE: To estimate the cost-effectiveness of malaria intermittent preventive 
      treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP). METHODS: In two 
      previous IPTi trials in Ifakara (United Republic of Tanzania) and Manhica 
      (Mozambique), SP was administered three times to infants before 9 months of age 
      through the Expanded Programme on Immunization. Based on the efficacy results of 
      the intervention and on malaria incidence in the target population, an estimate 
      was made of the number of clinical malaria episodes prevented. This number and an 
      assumed case-fatality rate of 1.57% were used, in turn, to estimate the number of 
      disability-adjusted life years (DALY) averted and the number of deaths averted. 
      The cost of the intervention, including start-up and recurrent costs, was then 
      assessed on the basis of these figures. FINDINGS: The cost per clinical episode 
      of malaria averted was US$ 1.57 (range: US$ 0.8-4.0) in Ifakara and US$ 4.73 
      (range: US$ 1.7-30.3) in Manhica; the cost per DALY averted was US$ 3.7 (range: 
      US$ 1.6-12.2) in Ifakara and US$ 11.2 (range: US$ 3.6-92.0) in Manhica; and the 
      cost per death averted was US$ 100.2 (range: US$ 43.0-330.9) in Ifakara and US$ 
      301.1 (range: US$ 95.6-2498.4) in Manhica. CONCLUSION: From the health system and 
      societal perspectives, IPTi with SP is expected to produce health improvements in 
      a cost-effective way. From an economic perspective, it offers good value for 
      money for public health programmes.
FAU - Hutton, Guy
AU  - Hutton G
AD  - Swiss Tropical Institute, Basel, Switzerland. guy.hutton@dev-sol-int.com
FAU - Schellenberg, David
AU  - Schellenberg D
FAU - Tediosi, Fabrizio
AU  - Tediosi F
FAU - Macete, Eusebio
AU  - Macete E
FAU - Kahigwa, Elizeus
AU  - Kahigwa E
FAU - Sigauque, Betuel
AU  - Sigauque B
FAU - Mas, Xavier
AU  - Mas X
FAU - Trapero, Marta
AU  - Trapero M
FAU - Tanner, Marcel
AU  - Tanner M
FAU - Trilla, Antoni
AU  - Trilla A
FAU - Alonso, Pedro
AU  - Alonso P
FAU - Menendez, Clara
AU  - Menendez C
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Bull World Health Organ
JT  - Bulletin of the World Health Organization
JID - 7507052
RN  - 0 (Antimalarials)
RN  - 0 (Drug Combinations)
RN  - 37338-39-9 (fanasil, pyrimethamine drug combination)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Antimalarials/*economics/therapeutic use
MH  - Cost-Benefit Analysis/*economics
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Infant
MH  - Malaria/*economics/epidemiology/*prevention & control
MH  - Male
MH  - Mozambique/epidemiology
MH  - Multivariate Analysis
MH  - Pyrimethamine/economics/therapeutic use
MH  - Sulfadoxine/economics/therapeutic use
MH  - Tanzania/epidemiology
PMC - PMC2636201
EDAT- 2009/03/11 09:00
MHDA- 2009/06/26 09:00
PMCR- 2009/02/01
CRDT- 2009/03/11 09:00
PHST- 2008/02/06 00:00 [received]
PHST- 2008/06/25 00:00 [accepted]
PHST- 2009/03/11 09:00 [entrez]
PHST- 2009/03/11 09:00 [pubmed]
PHST- 2009/06/26 09:00 [medline]
PHST- 2009/02/01 00:00 [pmc-release]
AID - S0042-96862009000200014 [pii]
AID - 10.2471/blt.08.051961 [doi]
PST - ppublish
SO  - Bull World Health Organ. 2009 Feb;87(2):123-9. doi: 10.2471/blt.08.051961.